Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis
Wen Zhao, Danlei Yu, Zhen Chen, Weilong Yao, Jin Yang, Suresh S. Ramalingam, Shi‐Yong Sun
Topics & Concepts
OsimertinibCancer researchApoptosisCell cultureMedicineEpidermal growth factor receptorChemistryBiologyCancerInternal medicineBiochemistryGeneticsErlotinibMelanoma and MAPK PathwaysLung Cancer Treatments and MutationsQuinazolinone synthesis and applications